Amgen oppose Regeneron in privilege dispute in US antitrust case over cholesterol drug
MLex Summary: Amgen wrote to a US magistrate judge to oppose Regeneron Pharmaceuticals’ letter regarding a privilege dispute in a case accusing Amgen of engaging in an anticompetitive drug bundling scheme...To view the full article, register now.
Already a subscriber? Click here to view full article